OKYO Pharma Ltd
OKYO2.030USD
+0.160+8.56%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
73.12MMarket Cap
LossP/E TTM
More Details of OKYO Pharma Ltd Company
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO Pharma Ltd Info
Ticker SymbolOKYO
Company nameOKYO Pharma Ltd
IPO dateJul 17, 2018
CEOJacob (Gary S)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJul 17
AddressFloor 4, 14/15 Conduit St
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW1S 2XJ
Phone442074952379
Websitehttps://okyopharma.com/
Ticker SymbolOKYO
IPO dateJul 17, 2018
CEOJacob (Gary S)
Company Executives of OKYO Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.83K
-0.11%
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
8.95K
--
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.83K
-0.11%
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
8.95K
--
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
1.39K
68.21%
UK
647.00
31.79%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cerrone (Gabriele M)
27.05%
Chernett (Jorey)
7.94%
Dauntless Investment Group, LLC
6.44%
Fonda (Laura)
5.13%
Northern Trust Investments, Inc.
0.15%
Other
53.30%
Shareholders
Shareholders
Proportion
Cerrone (Gabriele M)
27.05%
Chernett (Jorey)
7.94%
Dauntless Investment Group, LLC
6.44%
Fonda (Laura)
5.13%
Northern Trust Investments, Inc.
0.15%
Other
53.30%
Shareholder Types
Shareholders
Proportion
Individual Investor
40.26%
Investment Advisor
6.55%
Investment Advisor/Hedge Fund
0.18%
Hedge Fund
0.15%
Other
52.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
13
2.77M
7.37%
-312.19K
2025Q2
19
15.34M
40.79%
+2.90M
2025Q1
18
11.42M
33.74%
+1.62M
2024Q4
16
10.37M
30.64%
+596.64K
2024Q3
16
10.34M
30.57%
+573.51K
2024Q2
17
9.70M
36.98%
+8.68M
2024Q1
17
9.60M
36.70%
+8.67M
2023Q4
16
9.54M
36.52%
+9.38M
2023Q3
14
8.78M
34.33%
+8.71M
2023Q2
7
49.05K
0.20%
-5.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cerrone (Gabriele M)
10.17M
27.05%
+894.51K
+9.64%
Jun 19, 2025
Chernett (Jorey)
2.30M
6.12%
+2.30M
--
May 23, 2025
Dauntless Investment Group, LLC
2.74M
7.27%
+747.00K
+37.56%
Jun 30, 2025
Jacob (Gary S)
45.83K
0.12%
-50.00
-0.11%
Jun 19, 2025
Renaissance Technologies LLC
--
0%
-13.95K
-100.00%
Jun 30, 2025
Citadel Advisors LLC
--
0%
-27.40K
-100.00%
Jun 30, 2025
Cerity Partners LLC
12.81K
0.03%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of OKYO Pharma Ltd?
The top five shareholders of OKYO Pharma Ltd are:
Cerrone (Gabriele M) holds 10.17M shares, accounting for 27.05% of the total shares.
Chernett (Jorey) holds 2.30M shares, accounting for 6.12% of the total shares.
Dauntless Investment Group, LLC holds 2.74M shares, accounting for 7.27% of the total shares.
Jacob (Gary S) holds 45.83K shares, accounting for 0.12% of the total shares.
Renaissance Technologies LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Cerrone (Gabriele M) holds 10.17M shares, accounting for 27.05% of the total shares.
Chernett (Jorey) holds 2.30M shares, accounting for 6.12% of the total shares.
Dauntless Investment Group, LLC holds 2.74M shares, accounting for 7.27% of the total shares.
Jacob (Gary S) holds 45.83K shares, accounting for 0.12% of the total shares.
Renaissance Technologies LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of OKYO Pharma Ltd?
The top three shareholder types of OKYO Pharma Ltd are:
Cerrone (Gabriele M)
Chernett (Jorey)
Dauntless Investment Group, LLC
Cerrone (Gabriele M)
Chernett (Jorey)
Dauntless Investment Group, LLC
How many institutions hold shares of OKYO Pharma Ltd (OKYO)?
As of 2025Q3, 13 institutions hold shares of OKYO Pharma Ltd, with a combined market value of approximately 2.77M, accounting for 7.37% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -33.42%.
What is the biggest source of revenue for OKYO Pharma Ltd?
In FY2025, the -- business generated the highest revenue for OKYO Pharma Ltd, amounting to -- and accounting for --% of total revenue.
